{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T16:57:41Z","timestamp":1783702661107,"version":"3.55.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2017,1,19]],"date-time":"2017-01-19T00:00:00Z","timestamp":1484784000000},"content-version":"vor","delay-in-days":18,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Voriconazole, a broad-spectrum antifungal, has been associated with visual and auditory hallucinations. We report the case of patient being treated with voriconazole for pulmonary aspergillosis who developed visual hallucinations and new suicidal ideation with plan. Voriconazole troughs were supratherapeutic (9.0 mcg\/mL) and the patient was positive for the CYP2C19*1\/*2 allele.<\/jats:p>","DOI":"10.1093\/ofid\/ofw215","type":"journal-article","created":{"date-parts":[[2017,2,12]],"date-time":"2017-02-12T08:26:52Z","timestamp":1486888012000},"source":"Crossref","is-referenced-by-count":7,"title":["Elevated Voriconazole Level Associated With Hallucinations and Suicidal Ideation: A Case Report"],"prefix":"10.1093","volume":"4","author":[{"given":"Jeffrey W.","family":"Jansen","sequence":"first","affiliation":[{"name":"PGY2 Infectious Diseases Pharmacy Resident and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumon K.","family":"Sen","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Specialist, VA St. Louis Health Care System, Missouri; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"Moenster","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Specialist, VA St. Louis Health Care System, Missouri; and"},{"name":"Department of Pharmacy Practice, St. Louis College of Pharmacy, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,1,19]]},"reference":[{"key":"2020081004464605800_CIT0001","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1179\/1973947812Y.0000000051","article-title":"Voriconazole in clinical practice","volume":"24","author":"Mikulska","year":"2012","journal-title":"J Chemother"},{"key":"2020081004464605800_CIT0002","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1086\/588844","article-title":"Hallucinations during voriconazole therapy","volume":"47","author":"Zonios","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020081004464605800_CIT0003","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-008-0114-3","article-title":"Visual disturbance comorbid with hallucination caused by voriconazole in the Japanese population","volume":"88","author":"Imataki","year":"2008","journal-title":"Int J Hematol"},{"key":"2020081004464605800_CIT0004","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N Engl J Med"},{"key":"2020081004464605800_CIT0005","doi-asserted-by":"crossref","first-page":"4793","DOI":"10.1128\/AAC.00626-12","article-title":"Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring","volume":"56","author":"Dolton","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020081004464605800_CIT0006","first-page":"739","article-title":"Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring","volume":"136","author":"Imhof","year":"2006","journal-title":"Swiss Med Wkly"},{"key":"2020081004464605800_CIT0007","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ijantimicag.2015.12.003","article-title":"Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections","volume":"47","author":"Lamoureux","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"2020081004464605800_CIT0008","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/jac\/dku031","article-title":"Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing","volume":"69","author":"Dolton","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"2020081004464605800_CIT0009","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijantimicag.2014.05.019","article-title":"Voriconazole pharmacokinetics and exposure-response relationships: assessing the links between exposure, efficacy and toxicity","volume":"44","author":"Dolton","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"2020081004464605800_CIT0010","volume-title":"Vfend (voriconazole) [package insert]","year":"2011"},{"key":"2020081004464605800_CIT0011","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJM200201243460403","article-title":"Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever","volume":"346","author":"Walsh","year":"2002","journal-title":"N Engl J Med"},{"key":"2020081004464605800_CIT0012","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1093\/infdis\/jiu017","article-title":"Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype","volume":"209","author":"Zonios","year":"2014","journal-title":"J Infect Dis"},{"key":"2020081004464605800_CIT0013","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1445-5994.2011.02454.x","article-title":"Voriconazole toxicity related to polymorphisms in CYP2C19","volume":"41","author":"Suan","year":"2011","journal-title":"Intern Med J"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/1\/ofw215\/33622173\/ofw215.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/4\/1\/ofw215\/33622173\/ofw215.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T08:47:28Z","timestamp":1597049248000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofw215\/2928233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,1]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofw215","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017]]},"published":{"date-parts":[[2017,1,1]]},"article-number":"ofw215"}}